Palier Gold : evidences validées mécaniquement, avec leur source primaire.
206 evidences · page 9 / 9
SARS-CoV-2 clearance was similar between malaria co-infected and non-co-infected groups by day 28 (adjusted risk ratio 0.99 [95% CI 0.79–1.24]; p=0.95).
KenyaCOVID-19 · paludismeobservé by day 28publié 2026The Lancet. Global healthPubMeddocument de 8 observations
17 %Among adolescents living with HIV in Kenya, 17% reported no longer being able to go to their regular clinic for medical care due to COVID-19.
KenyaCOVID-19publié 2021AIDS and behaviorPubMeddocument de 6 observations
23 %Among adolescents living with HIV in Kenya, 23% reported no longer being able to go outside due to COVID-19.
KenyaCOVID-19publié 2021AIDS and behaviorPubMeddocument de 6 observations
32,4 %In Nairobi, seroprevalence of anti-SARS-CoV-2 IgG was 32.4% (95% CI 23.1–42.4%) at the beginning of the study period.
KenyaCOVID-19publié 2022PLOS global public healtheurope_pmcdocument de 7 observationsDOI 10.1371/journal.pgph.0000883
29 lineages29 Pango lineages were detected across six counties of Coastal Kenya during Wave 2 of SARS-CoV-2 infections.
KenyaCOVID-19observé Wave 2publié 2022eLifeeurope_pmcdocument de 6 observations
37 casesAmong 97 SARS-CoV-2 cases in Laikipia county, Kenya, the Omicron variant was detected in 37 cases.
KenyaCOVID-19observé 24th April to 31st December 2021publié 2023Temporal distribution and clinical characteristics of the Alpha, Delta and Omicron SARS-Coeurope_pmcdocument de 10 observations
Chaque ligne mène à son document source. Le nombre indiqué est celui des observations VALIDÉES qu'il porte, jamais celui des observations extraites : les deux diffèrent sur la plupart des documents. L'extrait exact du texte source n'est pas publié, par contrainte de droit d'auteur.